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In carcinoma, cancer-associated fibroblasts participate in 
force-mediated extracellular matrix (ECM) remodeling, con-
sequently leading to invasion of cancer cells. Likewise, the 
ECM remodeling actively occurs in glioblastoma (GBM) and 
the consequent microenvironmental stiffness is strongly linked 
to migration behavior of GBM cells. However, in GBM the 
stromal cells responsible for force-mediated ECM remodeling 
remain unidentified. We show that tumor-associated mesen-
chymal stem-like cells (tMSLCs) provide a proinvasive matrix 
condition in GBM by force-mediated ECM remodeling. 
Importantly, CCL2-mediated Janus kinase 1 (JAK1) activation 
increased phosphorylation of myosin light chain 2 in tMSLCs 
and led to collagen assembly and actomyosin contractility. 
Collectively, our findings implicate tMSLCs as stromal cells 
providing force-mediated proinvasive ECM remodeling in the 
GBM microenvironment, and reminiscent of fibroblasts in 
carcinoma. [BMB Reports 2018; 51(4): 182-187]
INTRODUCTION
Glioblastoma (GBM) is the most common and aggressive 
primary brain tumor in adults (1). Despite the advent of 
modern medical treatments, median survival is still less than 
15 months, and long-term survival is extremely rare (2). The 
poor prognosis of GBM is attributed to the diffuse and 
unrelenting infiltration of tumor cells throughout the brain 
despite optimal treatment (2, 3). 
Although there are many mechanisms involved in invasion 
of GBM cells, extracellular matrix (ECM) remodeling has 
received much attention due to its direct interaction with GBM 
cells in the tumor microenvironment. Indeed, infiltration of 
GBM correlated with the ability to alter the properties of the 
surrounding extracellular space and to interact with its 
components (4, 5).
Since the role of ECM in cancer progression has begun to be 
understood (6, 7), its importance to GBM has also drawn great 
attention. Generally, ECM has been regarded as a hurdle that 
cancer cells must overcome to enter the blood vessels for 
metastasis to other organs. Accordingly, invasion of metastatic 
cancer cells throughout ECM has been thought to be enabled 
by protease-mediated matrix degradation that makes a 
movement track for migration of cancer cells. In line with this 
notion, there was a strong correlation between activation of 
matrix metalloproteinases (MMPs) that degrade ECM and 
invasiveness of GBM (8). Alternatively, instead of protease- 
mediated matrix remodeling, cancer cell invasion in ECM 
environment could be enabled by force-mediated rearrangement 
of ECM that gives a mechanical stiffness in tumor micro-
environment (9-11). Indeed, many tumors, including GBM, are 
mechanically stiffer than the surrounding stroma (12, 13). 
Interestingly, glioma migration and proliferation were affected 
by rigidity of ECM (14). Although both protease- and 
force-mediated ECM remodeling contribute to invasion of 
cancer cells, the mechanism underlying force-mediated matrix 
remodeling is largely unexplored in brain tumors.
In the case of carcinoma, ECM is highly produced and 
remodeled by carcinoma-associated fibroblasts (CAFs) (15). 
Although soluble factors secreted by CAFs play a role in 
malignant phenotypes of cancer, CAFs also contributed to 
invasiveness of cancer cells by force-mediated ECM re-
modeling using actomyosin contractility through Rho-Rho-kinase 
(ROCK) signaling (11). Likewise, GBM is also known to be 
mechanically stiffer than the surrounding parenchyma and 
force-mediated ECM remodeling has been observed as an 
important parameter in GBM progression (6, 7). In contrast to 
carcinoma, however, the equivalent stromal cells responsible 
for the stiffness in GBM remain unknown. 
Among stromal cells, mesenchymal stem cells (MSCs) have 
been recently identified as stromal components in many 
cancers, including GBM (16-19). Since MSCs have wound 
tropism and the potential to repair damaged tissues by ECM 
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Fig. 1. tMSLCs-mediated ECM remodeling enhances invasiveness 
of GBM cells. (A, B) Schematic illustration (A) and quantification
(B) of GBM cell invasion in collagen-based gel matrix premixed 
with tMSLC0903. (C) Schematic illustrating the experimental scheme
for analysis of GBM cell invasiveness in collagen-based ECM 
preconditioned by tMSLC0903. (D) H&E staining (upper panel) 
and collagen staining with Sirius red (lower panel). Quantification
of X01 GBM cells infiltrated into the collagen-based matrix 
preconditioned by tMSLCs (right panel). Scale bar, 100 μm. (E, F) 
Quantification of matrix contraction by X01 GBM cells (E) and 
tMSLC0903 (F). Upper panel shows scanned images of the 
contracted gel. Data are presented as mean ± SD from one of 
three independent experiments performed. **P ＜ 0.01 vs. control;
***P ＜ 0.001 vs. control.
Fig. 2. JAK1 activation is required for ECM remodeling ability of 
tMSLCs. (A) Quantification of matrix contraction by tMSLC0903 
treated with pharmacological inhibitors against oncogenic signaling 
components as indicated. (B-D) Quantification of matrix contraction
by tMSLC0903 treated with pan-JAK inhibitor P6 (B), JAK2/STAT3 
inhibitor WP1066 (C), or with siRNAs against JAK1 (D). (E) H&E 
staining (upper panel) and collagen staining with Sirius red (lower 
panel). Quantification of GBM cell invasion in collagen-based 
matrix preconditioned by tMSLCs treated with siRNAs as indicated 
(right panel). (F) H&E staining (upper panel) and collagen staining 
with Sirius red (lower panel). Quantification of X01 GBM cell 
invasion in collagen-based matrix preconditioned by tMSLCs treated
with pan-JAK inhibitor P6 or JAK2/STAT3 inhibitor WP1066 (right 
panel). Data are presented as mean ± SD from one of three 
independent experiments performed. *P ＜ 0.05 vs. control; **P ＜
0.01 vs. control; ***P ＜ 0.001 vs. control.
remodeling (20, 21), we speculated that tumor-associated 
mesenchymal stem-like cells (tMSLCs) in GBM may provide 
mechanical stiffness and facilitate the motility of GBM cells. 
Accordingly, we investigate whether tMSLCs could generate 
force-mediated ECM remodeling and provide a proinvasive 
matrix environment in GBM that is reminiscent of CAFs.
RESULTS
tMSLCs-induced ECM remodeling enhances invasion of 
GBM cells
In a previous study, we established human tMSLCs from 
glioma specimens (22). Those cells were non-tumorigenic and 
similar to mesenchymal stem cells (23), based on their 
spindle-shaped morphology and expression of MSC surface 
antigens (CD105, CD73, and CD90), but not leukocyte 
(CD45), endothelial cell (CD31), or pericyte (NG2) markers. In 
parallel, these cells were able to differentiate into tri-lineage 
mesenchymal cells, including osteogenic, adipogenic, and 
chondrogenic cells. To investigate the effect of tMSLCs on 
invasiveness of GBM cells, we analyzed infiltration of X01 
GBM cells in coculture with or without tMSLC0903 in a 
collagen-based matrix, a similar composition to that of in vivo 
basement membrane, in which collagen type I and matrigel 
were mixed and solidified in a growth medium (Fig. 1A). 
Compared to GBM cells alone, invasion of GBM cells was 
increased by the presence of tMSLCs in the matrix (Fig. 1B). 
Although tMSLCs stimulate GBM cells with soluble factors or 
cell-to-cell contact, we were more interested in whether 
tMSLCs contribute to invasion of GBM cells by their ECM 
remodeling capability. To clarify, tMSLCs were cultured in a 
collagen-based matrix and allowed ECM remodeling for 3 days 
before killing the cells with puromycin, followed by washing 
out cell debris and soluble factors, and seeding of X01 GBM 
cells on top of the matrix (Fig. 1C). Importantly, GBM cells 
were more invasive in the matrix that has been remodeled by 
tMSLCs than in the matrix where ECM was not remodeled by 
tMSLCs (Fig. 1D). By collagen staining with Sirius red, we also 
noticed that collagen staining is intensive in the matrix 
conditioned by tMSLCs (Fig. 1D). Although the increase in 
Sirius red staining could be due to the collagen-rich condition, 
it could be also caused by formation of collagen bundles. 
Accordingly, we further measured the ability of the tMSLCs to 
contract collagen matrix. As expected, gel contraction increased 
as the number of tMSLCs increased, whereas X01 GBM cells 
demonstrated no capability to contract gel (Fig. 1E, F). Taken 
together, these results implicate that tMSLCs contribute to 
invasiveness of GBM cells via force-mediated ECM remodeling.
JAK1 activation is required for ECM remodeling ability of 
tMSLCs
Given that tMSLCs promote invasion of GBM cells through 
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Fig. 3. JAK1 activation in tMSLCs regulates actomyosin contractility.
(A, B) Western blot analysis for p-MLC2 in tMSLC0903 after 
treatment with siRNAs against JAK1 (A) or pan-JAK inhibitor P6 
(B). β-actin was used for a loading control. (C) Quantification of 
matrix contraction by tMSLC0903 treated with the ROCK inhibitor 
Y-27632. (D) Western blot analysis for p-MLC2 in tMSLC0903 
after treatment with Y-27632. (E) H&E staining (upper panel) and 
collagen staining with Sirius red (lower panel). Quantification of 
X01 GBM cell invasion in collagen-based matrix preconditioned 
by tMSLCs treated with Y-27632 (right panel). (F) X01 GBM cell 
invasion in collagen-based matrix preconditioned by tMSLCs 
treated with ML-7. Representative photos are shown in upper 
panel. Western blot analysis for p-MLC2, a downstream effector 
of ML-7 in lower panel. Invasion of X01 GBM cells is quantified 
by counting three randomly selected microscopic fields (right 
panel). (G) Western blot analysis for p-MLC2 in tMSLC0903 after 
treatment with WP1066. Data are presented as mean ± SD from 
one of three independent experiments performed. **P ＜ 0.01 vs. 
control; ***P ＜ 0.001 vs. control.
force-mediated ECM remodeling, we next sought to define the 
signaling factor that regulates contractile force in tMSLCs. After 
treatment with various chemical inhibitors against signaling 
pathways involved in GBM progression, we found that 
inhibition of JAK, SRC, or PIM1/2 suppresses the ability of 
tMSLCs to contract collagen gels (Fig. 2A). More significantly, 
treatment with the pan-JAK inhibitor P6 effectively decreased 
gel contraction in a dose-dependent manner, indicating that 
JAK1/2 in tMSLCs can be a critical regulator for ECM 
remodeling (Fig. 2B and Fig. S1A). Meanwhile, treatment with 
WP1066 inhibiting both JAK2 and STAT3 did not affect gel 
contraction (Fig. 2C and Fig. S1B). In parallel with these 
results, treatment with siRNAs (small interfering RNA) against 
JAK1/2 attenuated the ability of tMSLCs to contract collagen 
matrix, albeit to a lesser extent in the case of JAK2 siRNA (Fig. 
2D). Consistently, when JAK1 was depleted, tMSLCs lost the 
ability to provide a proinvasive ECM microenvironment (Fig. 
2E). Also, when collagen was stained with Sirius red, we 
observed that JAK1 depletion in tMSLCs diminishes the 
collagen assembly in the matrix (Fig. 2E and Fig. S1C). 
Treatment with pan-JAK inhibitor P6 supported that obser-
vation by confirming the role of JAK in tMSLCs on proinvasive 
matrix remodeling and collagen assembly (Fig. 2F). However, 
targeting of STAT3 with siRNA or WP1066 consistently had no 
effect on gel contraction, proinvasive ECM remodeling, or 
collagen assembly (Fig. 2D-F and Fig. S1C). Collectively, our 
results suggest that tMSLCs provide a proinvasive ECM 
microenvironment through JAK1-mediated contractile force.
JAK1 activation in tMSLCs regulates actomyosin contractility 
Phosphorylation of myosin light chain 2 (MLC2) is well known 
as a molecular signature of actomyosin contractility in CAFs. 
Because the above data was reminiscent of actomyosin 
contractility by CAFs in carcinoma (11), we next examined 
whether JAK1 in tMSLCs is also able to regulate phosphory-
lation of MLC2. Abrogating JAK1 expression with two different 
siRNAs decreased MLC2 phosphorylation in tMSLCs (Fig. 3A). 
In agreement with the data, treatment with pan-JAK inhibitor 
P6 also reduced MLC2 phosphorylation, indicating that 
tMSLCs may generate force-mediated matrix remodeling in 
GBM through JAK1-mediated actomyosin contractility as CAFs 
in carcinoma (Fig. 3B).
In view of these results, we further examined whether 
tMSLCs in GBM are also involved in actomyosin contractility 
by a similar regulatory mechanism that was seen in CAFs. 
Because ROCK activity is regulated by JAK1 in CAFs and 
participated in actomyosin contractility (10), we tested whether 
treatment with the ROCK inhibitor Y-27632 could diminish 
the effect of tMSLCs on gel contraction. Importantly, the 
contractile force and p-MCL2 level in tMSLCs was decreased 
by treatment with Y-27632 in a dose-dependent manner (Fig. 
3C, D). More importantly, treatment with Y-27632 diminished 
the ability of tMSLCs that assemble collagen and provide a 
proinvasive ECM condition (Fig. 3E). 
To further confirm that JAK1/ROCK-dependent contractile 
force occurs by MLC2-involved actomyosin contractility, we 
tested whether direct targeting of MLC2 phosphorylation could 
also attenuate the effect of tMSLCs on proinvasive ECM 
remodeling. To this end, we treated tMSLCs with an ML-7 
myosin light chain kinase (MLCK) inhibitor during ECM 
remodeling in a collagen-based matrix, and then those cells 
were killed by puromycin and washed out before seeding with 
X01 GBM cells, as shown in Fig. 1C. In agreement with the 
above data, treatment with ML-7 markedly suppressed the 
effect of tMSLCs on proinvasive ECM remodeling (Fig. 3F). 
However, also consistent with the above data, treatment 
with JAK2/STAT3 inhibitor WP1066 did not affect MLC2 
phosphorylation (Fig. 3G). Because STAT3 is also a critical 
regulator for actomyosin contractility in CAFs, JAK1-dependent 
actomyosin contractility in tMSLCs is unlikely to use the same 
downstream effectors. Taken together, these results indicate 
that tMSLCs contribute to force-mediated ECM remodeling in 
GBM by the same actomyosin contractility that was seen in 
CAFs.
CCL2-mediated JAK1 activation in tMSLCs regulates 
actomyosin contractility
Since JAK is activated mainly by cytokines, we sought to 
discover cytokines that are involved in ECM remodeling. In 
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Fig. 4. CCL2-mediated JAK1 activation in tMSLCs regulates acto-
myosin contractility. (A) Quantification of matrix contraction by 
tMSLC0903 treated with siRNA as indicated. (B) Quantification of 
matrix contraction by tMSLC0903 treated with siRNA against 
CCL2. (C) H&E staining (upper panel) and collagen staining with 
Sirius red (lower panel). Quantification of X01 GBM cell invasion 
in collagen-based matrix preconditioned by tMSLCs treated with 
siRNAs against CCL2 (right panel). (D) Western blot analysis for 
p-JAK1 and p-MLC2 in tMSLCs treated with siRNAs against CCL2 
(upper). qRT-PCR was performed to validate CCL2 siRNA efficiency
(lower). (E) Kaplan-Meier survival curves of patients with brain 
tumors in high and low levels of CCL2. (F) Schematic model 
illustrating force-mediated proinvasive ECM remodeling by tMSLCs 
in GBM microenvironment. Data are presented as mean ± SD from
one of three independent experiments performed. *P ＜ 0.05 vs. 
control; **P ＜ 0.01 vs. control; ***P ＜ 0.001 vs. control.
our previous study, we already noted the differential levels of 
cytokines in between tMSLCs and GBM cells (24). Because 
C5a, GRO alpha, IL6, IL8, and CCL2 are highly secreted from 
tMSLCs, we examined the effect of these cytokines on the 
contractile force of tMSLCs. Importantly, siRNA-mediated 
down-regulation of CCL2 especially reduced the contractile 
force of tMSLCs (Fig. 4A and Fig. S2). This result was 
confirmed using two different siRNA against CCL2 (Fig. 4B). 
Because JAK1-mediated actomyosin contractility provided 
proinvasive ECM, we also examined whether inhibition of 
CCL2 attenuates the ability of tMSLCs that provide proinvasive 
ECM. As expected, treatment with CCL2 siRNA diminished the 
ability of tMSLCs in proinvasive ECM remodeling and collagen 
assembly (Fig. 4C). Accordingly, CCL2 depletion decreased 
p-JAK and p-MLC2 in tMSLCs (Fig. 4D). However, because 
CCL2 could also directly affect a phenotypic change of GBM 
cells into invasiveness instead of actomyosin contractility, we 
next examined the possibility by treatment of GBM cells with 
recombinant human (rh) CCL2 prior to migration assay in 
transwell. Treatment with rhCCL2 appears to enhance 
migration of GBM cells; however, it was not enough to reach 
statistical significance (Fig. S3). 
More importantly, evaluation of data in REMBRANDT 
public database revealed that CCL2 levels are inversely 
correlated with the survival of patient with brain tumor (Fig. 
4E), adding to the clinical importance of CCL2. Taken 
together, our findings reveal that tMSLCs behave as stromal 
cells that promote a proinvasive ECM microenvironment 
through CCL2/JAK1/MLC2 signal-mediated contractile force in 
GBM as illustrated in Fig. 4F.
DISCUSSION
ECM is commonly disorganized in cancer, consequently 
causing mechanical stiffness in the tumor microenvironment 
(6, 9). For a long time, the disorganization of ECM in tumors 
was simply regarded as a result of tumor growth. However, 
several strong lines of evidence have revealed that the 
mechanical aberrations could actively instruct malignant 
progression in cancer as well as providing physical track 
generation for migratory cancer cells (6, 11). In carcinoma, 
CAFs participate in force-mediated ECM remodeling using 
actomyosin contractility (9, 10). The contractile force generated 
by actomyosin contractility in CAFs has been shown to play a 
critical role in both collective and individual migration of 
cancer cells. Intriguingly, abnormal ECM dynamics resembling 
carcinoma is also observed in GBM; however, the stromal 
cells contributing to stiffness caused by ECM remodeling in 
GBM remain obscure. 
No fibroblast has been found in the brain in contrast to the 
non-nervous system. Meanwhile, MSCs are present in the 
brain and are well known to play a role in wound tropism and 
to have the potential to repair damaged tissues by ECM 
remodeling (20, 21). Thus, we investigated whether tMSLCs 
act as the stromal cells providing the stiffness in the brain 
tumor microenvironment by force-mediated ECM remodeling. 
Notably, tMSLCs had a higher capability to contract a 
collagen-based gel matrix by actomyosin contractility than 
GBM does. Importantly, force-mediated ECM remodeling 
caused by tMSLCs provided a proinvasive microenvironment 
in GBM. The extent of gel contraction was dependent on 
CCL2-mediated JAK1 activation in tMSLCs. As further evidence, 
blocking JAK1 with either siRNA or pan-JAK inhibitor in 
tMSLCs effectively attenuated MLC2 phosphorylation and gel 
contraction, implicating that tMSLCs promote actomyosin 
contractility through JAK signaling. Previously, JAK1 signaling 
has shown to intervene in actomyosin contractility in CAFs (9, 
10). In line with the previous studies, our observation under-
scores the pivotal role of JAK1 on actomyosin contractility. 
In CAFs, depletion of STAT3 downstream of JAK1 also 
caused diminished levels of p-MLC2 and CAF matrix- 
remodeling (10). In contrast, however, inhibition of STAT3 in 
tMSLCs had no effect on MLC2 phosphorylation, actomyosin 
contractility and proinvasive ECM remodeling, even though it 
is regulated by JAK1, indicating that force-mediated ECM 
remodeling is regulated through JAK1, but not STAT3 in 
tMSLCs. Hence, JAK1 activation is necessary for matrix 
remodeling in both CAFs and tMSLCs; however, they may use 
tMSLCs promotes proinvasive stiffness in GBM
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the differential downstream effectors of JAK1 for actomyosin 
contractility.
Aberrant cytokine signaling is a key feature of the tumor 
microenvironment. Since cytokine interaction with its specific 
receptor triggers the recruitment of JAKs to the receptors in 
close proximity, it is not surprising that cytokines are engaged 
in actomyosin contractility as addressed in previous studies (9, 
10). In line with this notion, we found that CCL2 cytokine 
activates JAK1 in tMSLCs and participates in force-mediated 
matrix remodeling and thereby contributes to a proinvasive 
tumor microenvironment. Several strong lines of evidence 
have already shown the importance of CCL2 in a glioma 
microenvironment. Chang et al. demonstrated that CCL2 
enhances the immunosuppressive tumor microenvironment by 
the recruitment of regulatory T cells and myeloid-derived 
suppressor cells (25). Zhang et al. reported that CCL2 
promotes invasion of glioma cells via crosstalk with microglia 
in the tumor microenvironment (26). In line with these 
previous studies, our finding also adds to the importance of 
CCL2 in the GBM microenvironment that enhances 
proinvasive ECM remodeling by activating JAK1 in tMSLCs.
Recently, tMSLCs have been reported as stromal cells 
interacting with GBM cells, and their potential role in tumor 
progression has received intensive attention (27, 28). However, 
it remains controversial whether tMSLCs in the tumor micro-
environment play a role in cancer promotion or suppression 
(29-33). These contrasting results could be caused by differences 
in their origin and/or the type of tumor. Thus, we previously 
isolated tMSLCs directly from human GBM surgical specimens 
and found that their presence is closely correlated with the 
prognosis of patients (28). In this current study, we provide 
another strong evidence that tMSLCs act as stromal cells 
promoting GBM progression by force-mediated proinvasive 
ECM remodeling.
In summary, our finding demonstrates that tMSLCs provide 
force-mediated proinvasive ECM remodeling through CCL2/ 
JAK1/MLC2 signaling node in GBM, similar to CAFs in 
carcinoma. Considering the significance of CAFs in cancer 
progression, the mechanism underlying tMSLC-induced ECM 
remodeling merits further investigation in GBM. 
MATERIALS AND METHODS
Detailed materials and experimental procedures are 
available in Supplementary Data.
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